Reza Zadno - Procept Biorobotics CEO President
| PRCT Stock | USD 96.11 0.52 0.54% |
CEO
Reza Zadno is CEO President of Procept Biorobotics Corp
| Age | 69 |
| Address | 150 Baytech Drive, San Jose, CA, United States, 95134 |
| Phone | 650 232 7200 |
| Web | https://www.procept-biorobotics.com |
Latest Insider Transactions
Reza Zadno Latest Insider Activity
Tracking and analyzing the buying and selling activities of Reza Zadno against Procept Biorobotics stock is an integral part of due diligence when investing in Procept Biorobotics. Reza Zadno insider activity provides valuable insight into whether Procept Biorobotics is net buyers or sellers over its current business cycle. Note, Procept Biorobotics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Procept Biorobotics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Reza Zadno few days ago Disposition of 1403 shares by Reza Zadno of Procept Biorobotics at 99.9601 subject to Rule 16b-3 | ||
Reza Zadno over two weeks ago Disposition of 10509 shares by Reza Zadno of Procept Biorobotics at 92.7386 subject to Rule 16b-3 | ||
Reza Zadno over two weeks ago Disposition of 4510 shares by Reza Zadno of Procept Biorobotics at 95.5819 subject to Rule 16b-3 | ||
Reza Zadno over a month ago Acquisition by Reza Zadno of 48575 shares of Procept Biorobotics subject to Rule 16b-3 |
Procept Biorobotics Management Efficiency
The company has return on total asset (ROA) of (0.1673) % which means that it has lost $0.1673 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3702) %, meaning that it created substantial loss on money invested by shareholders. Procept Biorobotics' management efficiency ratios could be used to measure how well Procept Biorobotics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.32 in 2024. At this time, Procept Biorobotics' Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 26.1 M in 2024.Similar Executives
| Found 13 records | CEO Age | ||
| Joel Becker | Neuropace | 56 | |
| Mark Throdahl | Orthopediatrics Corp | 73 | |
| Albert DaCosta | Paragon 28 | 51 | |
| Glendon French | Pulmonx Corp | 62 | |
| Juan Quiros | Establishment Labs Holdings | 51 | |
| Gary Maharaj | SurModics | 61 | |
| Karen Zaderej | Axogen Inc | 62 | |
| Steven Williamson | Pulmonx Corp | 51 | |
| Massimo Calafiore | Orthofix Medical | 52 | |
| Damien McDonald | LivaNova PLC | 59 | |
| Ronald MD | Rxsight | 61 | |
| Vladimir Makatsaria | LivaNova PLC | 51 | |
| Joseph Dziedzic | Integer Holdings Corp | 56 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 |
Procept Biorobotics Corp Leadership Team
Elected by the shareholders, the Procept Biorobotics' board of directors comprises two types of representatives: Procept Biorobotics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procept. The board's role is to monitor Procept Biorobotics' management team and ensure that shareholders' interests are well served. Procept Biorobotics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procept Biorobotics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew CFA, Vice Relations | ||
| Hisham Shiblaq, Executive Officer | ||
| Stacey Porter, Chief Officer | ||
| Minni Vittal, VP Officer | ||
| Reza Zadno, CEO President | ||
| Kevin Waters, Executive CFO | ||
| Alaleh Nouri, Chief EVP | ||
| Mohan Sancheti, Senior Operations | ||
| Thomas Yorkey, VP RD | ||
| Bijesh Chandran, Senior Assurance | ||
| Barry Templin, Executive Development |
Procept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Procept Biorobotics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 5.06 B | ||||
| Shares Outstanding | 54.11 M | ||||
| Shares Owned By Insiders | 4.60 % | ||||
| Shares Owned By Institutions | 86.33 % | ||||
| Number Of Shares Shorted | 6.37 M | ||||
| Price To Book | 21.44 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.